What Can We Expect From Gilead Sciences (NASDAQ:GILD) After Atlantic Equities’s Latest Coverage?

Share

Why Has Atlantic Equities Given Gilead Sciences (NASDAQ:GILD) a $111.00 Price Target

Equities researchers at Atlantic Equities have initiated coverage on Gilead Sciences (NASDAQ:GILD) with a key “Neutral” rating. The Estimated Target Price for GILD is $111.00. It would indicate a possible upside of 9.37% from firm’s current stock price.

From a total of 15 analysts covering Gilead Sciences (NASDAQ:GILD) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $138 while the lowest target price is $102. The mean of all analyst targets is $125.2 with a 25.50% above today’s ($101.6) stock price. Gilead Sciences was the topic of 21 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Wells Fargo maintained shares on December 4 with “Market Perform” rating. Vetr upgraded shares to “Buy” rating and $129.16 target share price in a report from an August 17. Maxim Group maintained GILD stock in a recent report from October 28 with “Buy” rating. Needham maintained the rating on July 29. Needham has a “Buy” rating and a $125 price target on shares. Finally, Jyske Bank upgraded the stock to “Strong Buy” rating in a report issued on a September 10.

The stock decreased 0.74% or $0.76 during the last trading session, striking $101.6. Approximately 15.30M shares of stock traded hands or 85.68% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 6.35% since May 15, 2015 and is downtrending. It has underperformed by 2.54% the S&P500.

The overall sentiment of institutions has increased to 1.52 in Q2 2015. Its up 0.36, from 1.16 in 2015Q2. The ratio improved, as 89 institutions have sold all the shares of Gilead Sciences, Inc. that they owned while 467 funds have taken shares off the table. 118 funds have purchased shares for the first time while 728 added to their positions. These institutions now hold 1.15 billion shares or 2.16% less than the 1.17 billion shares they owned in 2015Q2.

The Fund Pathstone Family Office Llc currently is holding shares equating to 15.89% of its total portfolio in Gilead Sciences, Inc. representing a total of 60,008 shares. Another fund,Healthinvest Partners Ab, is holding a total of 249,300 shares equating to 14.48% of their holdings. Additionally, Domini Social Investments Llc has a 8,798 share stake in Gilead Sciences, Inc. which represents 14.12% of their total portfolio. The Fund, R. G. Niederhoffer Capital Management Inc, based out of New York, has also built up a stake in the stock, which represents a total of 12.17% of their total portfolio. Finally Hollow Brook Wealth Management Llc, a fund which is based in the state of New York reported a total holdings of 239,473 shares.

Insider activity is a very important aspect to track on any stock. Going back to March 4, 2015, shareholders of Gilead Sciences, Inc. have witnessed 0 insider buys, and a total of 30 sales equating to a net activity of approximately $174.75 million . Alton Gregg H sold 5,000 shares worth approximately $550,000. Cogan John Francis sold 15,000 shares worth approximately $1.65 million. Bischofberger Norbert W sold 70,000 shares worth approximately $7.00M. Milligan John F sold 100,000 shares worth approximately $9.92 million. The company insider Carter Paul Rutherford sold 2,000 shares worth $197,180.

Gilead Sciences, Inc. , is a research biopharmaceutical firm that discovers, develops and commercializes innovative medicines. The company has a market cap of $147.52 billion. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. It has 9.31 P/E ratio. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta.

According to Zacks Investment Research, “Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.”

COMMENTS: